Lisata Therapeutics Reports Q2 2025 Financial Results

Lisata Therapeutics, Inc. ( (LSTA) ) has released its Q2 earnings. Here is a breakdown of the information Lisata Therapeutics, Inc. presented to its investors.

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases, utilizing its proprietary cyclic peptide product candidate, certepetide. In its latest earnings report, Lisata Therapeutics highlighted its financial results for the second quarter of 2025, alongside significant progress in its clinical development programs. The company reported a cash runway extending into the fourth quarter of 2026, with no debt, ensuring funding for its current clinical programs through their next data milestones.

The key financial metrics for the second quarter of 2025 included a total revenue of $70,000, primarily from a license fee agreement with Catalent, Inc. Operating expenses decreased by 10.6% compared to the same period in 2024, totaling $4.9 million. Research and development expenses also saw a reduction, contributing to an overall net loss of $4.7 million, an improvement from the $5.0 million loss in the previous year. The company maintains a strong cash position with approximately $22.0 million in cash, cash equivalents, and marketable securities.

Lisata’s development portfolio is centered around certepetide, which has shown promising results in enhancing the efficacy of anti-cancer therapies in solid tumor models. The ASCEND trial demonstrated positive trends in overall survival for pancreatic cancer patients, while the BOLSTER trial accelerated its data readout timeline due to rapid enrollment. Additionally, Lisata’s strategic collaborations with Catalent and GATC Health Corp aim to optimize drug discovery and development processes.

Looking ahead, Lisata Therapeutics remains committed to advancing its clinical trials and exploring new indications for certepetide. The company anticipates several data milestones over the next 1.5 years, with management confident that its current financial resources will support operations through late 2026, ensuring continued progress in its mission to develop effective cancer treatments.